Introduction
PIK3CA, which codes for the p110a catalytic subunit of class IA phosphatidylinositol-3-kinase (PI3K), is implicated as an oncogene (Shayesteh et al., 1999) . The importance of PI3K signaling in cancer is unquestionable, as increased PI3K activity has been observed in many different cancer types and believed to be one of the driving forces behind tumorigenesis (Manning and Cantley, 2007) . Previous studies of knockout mice have demonstrated that an imbalance in the levels of the p110 catalytic and p85 regulatory subunits suffices to affect PI3K activity significantly (Ueki et al., 2002) . Similarly, elevated p110a levels correlate with increased PI3K activity (Shayesteh et al., 1999) . Therefore, it is of significance to delineate the mechanisms that increase p110a levels and thereby the PI3K activity in cancer. In addition, gene deletion studies in mice have shown that p110a is essential for growth factor signaling as well as for oncogenic transformation (Zhao et al., 2006) , whereas direct interaction of Ras with p110a is required for oncogenic Ras-induced tumorigenesis (Gupta et al., 2007) . Moreover, activating PIK3CA mutations, observed in many different cancers, are also shown to be transforming (Bader et al., 2006; Horn et al., 2008; Zhang et al., 2008) and increased expression of mutant PIK3CA further induces PI3K activity . All these studies indicate the importance of p110a in cancer and the significance of understanding the mechanisms that lead to its expression.
Unfortunately, despite the importance of PIK3CA in cancer, there is relatively little known about what regulates its transcription. We recently characterized the 5 0 -untranslated region (5 0 UTR) of PIK3CA and published the first report on the transcriptional regulation of this important oncogene (Astanehe et al., 2008) . We demonstrated that PIK3CA transcription is repressed by the tumor suppressor protein p53 in ovarian surface epithelial cells, and provided evidence to show that loss of p53 in ovarian cancer is one mechanism that leads to elevated p110a levels (Astanehe et al., 2008) . In addition, it has recently been demonstrated that the forkhead transcription factor, FOXO3a, induces PIK3CA by directly binding to its promoter rendering chronic myelogenous leukemia cells resistant to doxorubicin (Hui et al., 2008) . However, the induction of PIK3CA by FOXO3a is paradoxical as it is a known tumor suppressor with its activation mediating apoptosis in cancers including those of the breast (Sunters et al., 2003) . Indisputably, more studies are required to identify transcriptional mediators of PIK3CA. In the present study, we set out to demonstrate transcriptional regulation of PIK3CA using a breast cancer model.
Breast cancer is a heterogeneous disease consisting of various subtypes (Sorlie et al., 2001) . One of the most aggressive is the basal-like breast carcinoma (BLBC) often referred to as 'triple-negative' breast cancers because they do not express estrogen or progesterone receptors and they do not overexpress HER-2 (Yehiely et al., 2006) . BLBC accounts for 15-25% of all breast cancers, and women diagnosed with it have short survival time and increased rates of relapse (Sorlie et al., 2001) . We recently reported that the expression of Y-box binding protein-1 (YB-1), an oncogenic transcription/translation factor implicated in many malignancies (Wu et al., 2007) , is associated with relapse and poor overall survival for all breast cancer subtypes (Habibi et al., 2008) . This followed a smaller study indicating that 73% of BLBC primary tumors overexpress YB-1 . Both serine/threonine kinases AKT (Sutherland et al., 2005) and the p90 ribosomal S6 kinase (RSK; Stratford et al., 2008) phosphorylate YB-1 on its S102 residue, thereby altering its nuclear trafficking. Within the nucleus, YB-1 binds to the inverted CCAAT elements known as YB-1-responsive elements (YREs) to affect transcription (Didier et al., 1988) . Given the importance of YB-1 in breast cancer we sought to understand how it globally regulates gene expression and therefore a genome-wide promoter screen was performed using the NimbleGen chromatin immunoprecipitation (ChIP)-onchip (COC) platform (Finkbeiner et al., 2009) . The COC, which provided the basis for the present study, demonstrated a 17.05-fold enrichment of PIK3CA promoter hybridization to the microarray as compared to the input control, suggesting that YB-1 may control the expression of PIK3CA by direct promoter occupancy. In the present study, we report the transcriptional induction of PIK3CA by an oncoprotein, namely YB-1. We show that YB-1 interacts directly with the PIK3CA promoter to induce its transcription, thereby leading to elevated p110a levels and PI3K activity. In addition, we demonstrate that YB-1 has a major impact in regulating the invasion of BLBC cells through its ability to induce PIK3CA directly, increasing PI3K activity and thereby urokinase plasminogen activator (uPA) production.
Results and discussion
YB-1 binds to the PIK3CA promoter at three validated sites The PIK3CA promoter region was characterized by us for the very first time (Astanehe et al., 2008) , enabling the study of PIK3CA transcriptional regulation. The 5 0 UTR of PIK3CA is more than 50 000 bp upstream of the translational start site that lies within exon 2 (Figure 1a ).
This 5
0 UTR consists of two alternate first exons (1a and 1b) that splice differentially with exon 2. Thereby, there are two alternate promoter regions 1a and 1b (Astanehe et al., 2008) . Evaluation of the PIK3CA promoter for YB-1 binding identified six putative sites ( Figure 1a) . It is important to note that although our study is focused on the PIK3CA promoter approximately 1 kb upstream of the transcriptional start site, there may be additional YB-1-binding sites outside this region. Three BLBC cell lines (SUM149, HCC1937 and MDA-MB-231) were used with four different sets of ChIP primers designed to encompass the potential YB-1-binding sites (Figure 1a) . Amplification of ChIP DNA obtained from SUM149 and HCC1937 cells determined binding to ChIP regions 1, 2 and 3 within promoter 1a, whereas binding was not evident to ChIP region 4 within promoter 1b (Figure 1a) . In MDA-MB-231 cells, YB-1 only occupied ChIP regions 2 and 3 ( Figure 1a) . Nevertheless, the ChIP analyses in the three different cell lines validated that YB-1 binds to several sites along the PIK3CA promoter, specifically promoter 1a. Therefore, electrophoretic mobility shift assays (EMSA) were used to further verify YB-1 binding to these sites. Nuclear extracts of SUM149 (Figure 1b ), HCC1937 (data not shown) or MDA-MB-231 (data not shown) cells were incubated with biotin-labeled oligonucleotides 1-5 corresponding to the putative YB-1-binding sites. With all three nuclear extracts, this produced intense binding that could be competitively inhibited with unlabeled oligonucleotides. Furthermore, co-incubation of the nuclear extracts with an YB-1 antibody caused a supershift identifying the oligonucleotidebound nuclear protein as YB-1. In addition, mutation of the YRE from CAAT to CCCC decreased binding of nuclear YB-1 to oligonucleotides 1, 3 and 4 (Figure 1c ), but not to oligonucleotides 2 and 5 (data not shown). The culmination of these studies indicates that YB-1 can bind to three YREs located at sites 1 (position À51 300 bp), 3 (position À50 785 bp) and 4 (position À50 745 bp) on the PIK3CA promoter ( Figure 1c ).
YB-1 binds to the PIK3CA promoter and induces its transcription independent of copy number gains or mutational status We next addressed whether binding of YB-1 to the PIK3CA promoter leads to its transactivation. Silencing YB-1 with two different small-interfering RNAs (siR-NA) (siYB-1#1 and siYB-1#2) in SUM149, HCC1937 and MDA-MB-231 cells attenuated PIK3CA promoter activity measured by a luciferase assay (Figure 2a) . Similarly, silencing YB-1 decreased the PIK3CA transcript ( Figure 2b ) and the p110a protein (Figure 2c ) levels in all three cell lines. Consistent with these findings the stable knockdown of YB-1 in SUM149 cells, with a short-hairpin RNA targeting a different site than the siRNA, decreased PIK3CA transcript and p110a protein levels (Supplementary Figure S1a) . The same effect was observed when SUM149 cells were infected with a lentiviral vector expressing shYB-1 (Supplementary The YB-1/PIK3CA/uPA network promotes invasion A Astanehe et al Figure S1b ) and in SUM149 cells with a conditional tetracycline-off shYB-1 (Supplementary Figure S1c) . Furthermore, induction of YB-1 with doxycycline (1 mg/ml) in immortalized mammary epithelial cells with a tetracycline-inducible YB-1 expression vector (HTRY#5), increased PIK3CA promoter activity, transcript and p110a protein levels (Figure 2d ). Thus, using multiple strategies of YB-1 interference, we consistently show that PIK3CA and its protein product p110a are dependent on this transcription factor.
It is interesting to note that neither of SUM149, HCC1937 nor MDA-MB-231 cell lines has known PIK3CA mutations (Hollestelle et al., 2007) 
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The YB-1/PIK3CA/uPA network promotes invasion A Astanehe et al genetic aberration found in breast cancer (Bachman et al., 2004; Samuels and Velculescu, 2004; Isakoff et al., 2005; Saal et al., 2005) . Moreover, expression of the mutant PIK3CA increases PI3K activity and has been shown to be transforming (Bader et al., 2006; Horn et al., 2008; Zhang et al., 2008) . Therefore, it is important to elucidate mechanisms that lead to expression of these activating mutants. The SUM102 cell line, which is of the BLBC subtype, carries the common genetic alteration in the PIK3CA kinase domain (exon 20; H1047R), whereas the MCF-7 cell line of the luminal subtype carries a mutation in the PIK3CA helical domain (exon 9; E542K) (Hollestelle et al., 2007) . Interestingly, silencing YB-1 in both SUM102 and MCF-7 cells decreased the PIK3CA transcript ( Figure 3a ) and p110a protein (Figure 3b ) levels, indicating that the expression of mutant PIK3CA is also dependent on YB-1.
Aside from the occurrence of activating mutations in PIK3CA, this oncogene can also be amplified in cancer. It has been reported that 9% (8 of 92) of primary breast cancers have PIK3CA amplifications ; we therefore sought to examine our BLBC cell lines for PIK3CA copy number changes. Array comparative genomic hybridization (aCGH) indicated a large segmental amplification encompassing the PIK3CA locus (3q26.32) in HCC1937 and MDA-MB-231 cell lines, but not in the SUM149 cells ( Figure 3c ). In addition, real-time quantitative PCR of breast cancer cell lines determined HCC1937 and MDA-MB-231 cells to have the highest PIK3CA copy number with 5.6 and 3.7 copies, respectively ( Figure 3d ). The presence of PIK3CA amplification in the HCC1937 and MDA-MB-231 cell lines indicates that YB-1 can also regulate the expression of amplified PIK3CA. Similarly, we have previously shown that YB-1 can regulate the transcription of another commonly amplified gene, Her-2 (Wu et al., 2006) . Combination of the data generated from various cell lines carrying different PIK3CA alterations suggests that regardless of whether PIK3CA is wild type, amplified or mutated its expression is induced by YB-1.
Moreover, because two out of five of the BLBC cell lines demonstrated PIK3CA copy number gains (Figure 3d ), it suggested that amplifications of PIK3CA may be a more common occurrence in the BLBC subtype. The report demonstrating amplification in 9% (8 of 92) of breast cancers included a mixed cohort of tumors that were not classified based on subtype . Therefore, we investigated PIK3CA genomic copy number changes in 10 archival BLBC specimens using aCGH. Specimens E, I and J (30%) showed large segmental gains at the PIK3CA locus (3q26.32), however, copy number changes were not observed in 3q for seven of the ten cases (A-D and F-H; Figure 3e ). Although based on a limited sample size, these results suggest that BLBC may have higher amplification frequencies on toward 30% compared to other breast cancer subtypes.
YB-1 induces PIK3CA transcription in a manner dependent on S102 phosphorylation We screened a panel of breast cancer cell lines (including BLBC, HER-2 and luminal subtypes) for the levels of total YB-1 (T-YB-1), phosphorylated YB-1 (P-YB-1 (S102)
) and p110a ( Figure 4a ). Strikingly, the BLBC cell lines, including the SUM149s, expressed the highest levels of P-YB-1 (S102) and p110a. The T-YB-1 levels, however, were similar among the different cancer cell lines, although higher relative to the nontumorigenic line (184htert; Figure 4a ). Consistent with these findings, silencing YB-1 in a SUM149 xenograft model resulted in loss of P-YB-1 (S102) and decreased p110a protein levels ( Figure 4b ). Given the significance of the S102 site to the transcriptional activity of YB-1, we addressed whether it is required for PIK3CA transactivation. PIK3CA promoter activity increased with overexpression of wild-type YB-1 (wt-YB-1) in SUM149, HCC1937 and MDA-MB-231 cells (Figure 4c ). In addition, expression of an activated phospho-mimic mutant of YB-1 (YB-1 S102D) further augmented the PIK3CA promoter activity, whereas no induction was observed with transfection of an inactive mutant of YB-1 (YB-1 S102A; Figure 4c ). Similarly, PIK3CA transcript ( Figure 4d ) and p110a protein ( Figure 4e ) levels increased with overexpression of wt-YB-1 and even more with YB-1 S102D. Expression of YB-1 S102A did not induce the transcript (Figure 4d ) or the protein (Figure 4e ) levels in SUM149 and HCC1937 cells, although it acted as a dominant negative Figure 1 Mapping Y-box binding protein-1 (YB-1)-binding sites on the PIK3CA promoter. (a) Schematic representation of six putative YB-1-binding sites on the PIK3CA promoter. Promoter 1a encompasses a 1 kb region upstream of exon 1a, whereas promoter 1b is upstream of exon 1b. Putative binding sites 1-5 are within PIK3CA promoter 1a, and site 6 is within promoter 1b. Nucleotide positions are indicated relative to the translational start site ( þ 1) within exon 2. The location of the chromatin immunoprecipitation (ChIP) PCR products relative to the potential YB-1-binding sites is also indicated. ChIP of SUM149 and HCC1937 cells demonstrated binding of YB-1 to ChIP regions 1, 2 and 3 within promoter 1a. Yet, ChIP of MDA-MB-231 cells indicated YB-1 binding to ChIP regions 2 and 3. YB-1 binding was not observed in promoter 1b region (ChIP 4). The IgY-negative control samples either demonstrated none or less binding compared to the YB-1 pull-down samples. Moreover, the input DNA amplified expected product with all primer sets. (b) Electrophoretic mobility shift assays (EMSA) demonstrated a shift using SUM149 nuclear extract and oligonucleotides 1-5 corresponding to putative YB-1-binding sites on promoter 1a. Competition reactions were performed with 800-fold excess of unlabeled oligonucleotide. Furthermore, a supershift was demonstrated using a YB-1 antibody (1 mg), identifying the oligonucleotide-bound nuclear protein as YB-1. This effect was not observed when an unrelated CREB antibody (1 mg) was used as a negative control for the supershift. (c) Mutation of the YB-1-responsive element (YRE) from CAAT to CCCC decreased binding of YB-1 in the SUM149 nuclear extract to oligonucleotides 1, 3 and 4, but not to oligonucleotides 2 and 5. Therefore, sites 1 (position À51 300), 3 (position À50 785) and 4 (position À50 745) within promoter 1a verified as YB-1-binding sites. Asterisk (*) indicates the verified YB-1-binding sites.
The YB-1/PIK3CA/uPA network promotes invasion A Astanehe et al and decreased both in the MDA-MB-231 cells. In addition, PIK3CA transcript and p110a protein levels increased in MCF-7 cells stably transfected with wt-YB-1, whereas decreased in those with stable YB-1 S102A (Supplementary Figure S2) . These data suggest a positive correlation between p110a and P-YB-1 (S102) and further demonstrate the importance of the S102 site for induction of PIK3CA.
Loss of YB-1 results in a decrease in PI3K activity and the downstream signaling Similar to the decrease in transcript and protein levels, silencing YB-1 or PIK3CA decreased PI3K activity as indicated by an in vitro kinase assay (Figure 5a ). Furthermore, this reduction in PI3K activity translated to a decrease in downstream signaling in SUM149 (Figure 5b ), a downstream target of the PI3K pathway, subsequent to silencing YB-1 or PIK3CA compared to the scrambled control. The S6RP is phosphorylated by p70S6 kinase which is activated downstream of AKT (Anjum and Blenis, 2008) . To our surprise, none of the three cell lines exhibited a decrease in P-AKT or P-p70S6K following YB-1 or PIK3CA knockdown. Therefore, we queried if loss of p110a affected P-S6RP levels in an AKTindependent manner. Alternatively, RSK is also known to phosphorylate S6RP on its Ser235/236 residue (Roux et al., 2007) . Indeed, similar to P-S6RP, P-RSK (S380) levels decreased after reduction in p110a subsequent to silencing YB-1 or PIK3CA. Therefore, in all three cell lines tested (SUM149, Figure 5b ; HCC1937, data not shown; MDA-MB-231, Figure 5b ), loss of p110a decreased P-RSK (S380) and P-S6RP (S235/236) in an AKT-independent manner. Interestingly, however, in SUM102 cells with an activating mutant PIK3CA, loss of p110a after YB-1 or PIK3CA silencing, decreased P-AKT (S473) in addition to P-RSK (S380) and P-S6RP (S235/236) ( Figure 5c ). Thus, we show for the first time that interrupting YB-1 has a major inhibitory effect on p110a kinase activity. Importantly, we placed RSK and S6RP as major components of the p110a downstream signaling cascade that further elucidates the impact of disrupting YB-1. However, it remains unclear why there is a shift in signaling toward the AKT pathway when PIK3CA is mutated. Recently published data further support our findings. Interestingly, She et al. (2008) used a potent inhibitor of AKT1 and AKT2 (AKTi-1/2) on various breast cancer cell lines and demonstrated that those with wild-type PIK3CA, including MDA-MB-231 that were used in our studies, were resistant to the effect of AKTi-1/2 even at concentrations leading to complete loss of P-AKT, whereas cells with PIK3CA mutations or HER2 amplifications were uniformly sensitive. They concluded that cells with PIK3CA mutations are dependent on AKT signaling whereas those with wild-type PIK3CA are not. Our data provide further evidence demonstrating that cells with wild-type PIK3CA do not signal (1 mg/ml) increased PIK3CA promoter activity, transcript and p110a protein levels. Asterisk (*) represents P-value o0.05 comparing the labeled group to the scrambled control.
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Our study introduces the importance of RSK in mediating p110a signaling. In accordance with our findings, She et al. (2008) demonstrated that inhibition of AKT1/2 in HCC1806, a triple-negative cell line with wild-type PIK3CA, did not reduce P-S6RP (S235/236) despite the fact that P-AKT (S473) and p70S6K (T389) levels The YB-1/PIK3CA/uPA network promotes invasion A Astanehe et al were decreased. We suspect this is because RSK remains activated. In support of this idea, RSK has been reported to phosphorylate S6RP on its S235/236 residue (Roux et al., 2007) . We showed that P-RSK levels decreased with the loss of p110a following YB-1 or PIK3CA knockdown (Figures 5b and c) , demonstrating that the phosphorylation of this protein is also PI3K dependent. Although RSK has been implicated in cancer (Carriere et al., 2008) , the current knowledge about its involvement in breast cancer is limited. Smith et al. (2005) reported that RSK activity is elevated in breast cancer and subsequent studies by the same group later reported this to be common to prostate cancers as well (Clark et al., 2005) . Interestingly, similar to AKT, RSK binds to substrates with RxRXXS motifs (Anjum and Blenis, 2008) ; thereby it is likely that they may have and p110a compared to the empty vector control SUM149 xenografts. DAPI (46-diamidino-2-phenyl indole) was used for nuclear staining. The scale bars indicate 10 mm. (c) The PIK3CA promoter activity increased with overexpression of wt-YB-1, and even more with the expression of YB-1 S102D (active phospho-mimic mutant), whereas no induction was observed with expression of YB-1 S102A (inactive mutant) compared to the vector control. (d) PIK3CA transcript levels, as determined by quantitative real-time RT-PCR, and (e) p110a protein levels as demonstrated by immunoblots, increased in SUM149, HCC1937 and MDA-MB-231 cells after expression of wt-YB-1 and further enhanced after expression of YB-1 S102D. No induction was observed after the expression of YB-1 S102A. The Flag antibody was used to detect the YB-1 constructs that are tagged with 3 Â Flag. Asterisk (*) represents P-value o0.05 comparing the labeled group to the scrambled control. Symbol c represents P-value o0.05 comparing the two indicated groups. compared to the scrambled control, but not of AKT (S473) and p70S6K (T389) . (c) In SUM102 cells harboring mutant PIK3CA, silencing YB-1 or PIK3CA decreased P-AKT (S473) , P-RSK (S380) and P-S6RP (S235/236) levels. (d) Membrane localization of P-PDK1 (S241) decreased in SUM149 cells after silencing YB-1 or PIK3CA compared to the scrambled control. Hoechst dye was used for nuclear staining.
The YB-1/PIK3CA/uPA network promotes invasion A Astanehe et al overlapping functions in cells. Indeed, we have recently demonstrated that RSK, similar to AKT, can phosphorylate YB-1 on its S102 residue in BLBC (Stratford et al., 2008) . Our findings suggest the presence of a positive feedback loop by which P-YB-1 (S102) induces p110a, increasing PI3K activity, thereby leading to further increases in P-RSK. The regulation of RSK is complex and is known to require phosphorylation by mitogen-activated protein kinase, phosphoinositide-dependent kinase-1 (PDK1) and its own C-terminal kinase domain (Anjum and Blenis, 2008) . PDK1 gets recruited to the cell membrane through binding of its pleckstrin homology domain to PtdIns(3,4,5)P 3 generated on PI3K activation (Vanhaesebroeck and Alessi, 2000) . Interestingly, silencing YB-1 or PIK3CA in SUM149 (Figure 5d ) and HCC1937 (data not shown) cells decreased localization of phosphorylated PDK1 (S241) to the cell membrane compared to the scrambled control, thereby suggesting reduced PI3K activity. This decrease in PDK1 membrane localization could provide an explanation for the parallel decrease in P-RSK levels after YB-1 or PIK3CA knockdown. However, it has been suggested that the phosphorylation of RSK by PDK1 can in some cell types be PI3K independent (Anjum and Blenis, 2008) . In regard to breast cancer, we ascertain that p110a uses the RSK pathway.
The YB-1/p110a/uPA network induces BLBC cell invasion Invasion is a fundamental cellular event and a defining feature of cancer that separates lesions that are benign from those that are malignant. Silencing YB-1 or PIK3CA decreased the number of SUM149 and HCC1937 cells invading through Matrigel (Figure 6a) . Interestingly, transfection of the YB-1 knockdown cells with a constitutively active p110a construct (p110a-CAAX) reversed this phenotype (Figure 6a ). This suggests that the regulation of invasion by YB-1 may be dependent on PI3K activity. To understand why this may be the case, we turned to the invasion protease uPA, as we previously reported that it is important for the motility of breast cancer cells in a PI3K-dependent manner (Dunn et al., 2001) . We confirmed that silencing uPA decreased invasion of SUM149 and HCC1937 cells through Matrigel (Supplementary Figure S3a) . Furthermore, silencing YB-1 decreased uPA transcript (Figure 6b ) and protein (Supplementary Figure S3b) levels in SUM149 and HCC1937 cells, and this effect was mirrored by knocking down PIK3CA (Figures 6b;  Supplementary Figure S3b) . These results were corroborated in MDA-MB-231 and MDA-MB-468 cells (data not shown). In addition, SUM149 cells expressing stable shYB-1 expressed 70% less uPA transcript and protein compared to control (data not shown). Interestingly, expression of p110a-CAAX in siYB-1-treated cells rescued both the uPA transcript (Figure 6b ) and protein (Supplementary Figure S3b) levels, suggesting that regulation of uPA by YB-1 may be dependent on PI3K activity. Furthermore, the uPA transcript ( Figure 6c ) and protein (Supplementary Figure S3c) levels increased with overexpression of wt-YB-1, further enhanced with expression of YB-1 S102D, whereas no change was observed with expression of YB-1 S102A. Combination of these findings suggests that uPA is induced by P-YB-1 (S102) in a PI3K-dependent manner. It has previously been shown that the PI3K signaling pathway regulates expression of uPA through activation of nuclear factor-kB (NFkB; Sliva et al., 2002) . NFkB is a dimer protein that is retained in the cytoplasm as an inactive form by binding to IkB. Phosphorylation of IkB leads to its degradation, and the release and entry of NFkB into the nucleus where it can interact with promoter sequences (Rayet and Gelinas, 1999) . RSK has been shown to phosphorylate IkBa on its S32/36 residue (Ghoda et al., 1997) . Silencing YB-1 or PIK3CA decreased P-RSK (S380) as well as its downstream target P-IkBa (S32/36) ( Figure 6d ). In addition, transfection of p110a-CAAX rescued both P-RSK (S380) and P-IkBa (S32/36) levels ( Figure 6d ). Therefore, decreased phosphorylation of RSK and thus IkBa (S32/36) may be one mechanism by which loss of p110a following YB-1 or direct PIK3CA knockdown reduces uPA levels and thereby decreases invasion.
Taken together, we report a novel regulation of PIK3CA by YB-1 and elucidate a pathway that leads to cellular invasion (Figure 7 ). Here we show that the expression of PIK3CA, whether wild type, mutant or amplified, is dependent on YB-1. Once p110a is induced its kinase activity is upregulated leading to the activation of signaling through either AKT or RSK depending on whether PIK3CA is mutated. Activated AKT (Sutherland et al., 2005) or RSK (Stratford et al., 2008) phosphorylates YB-1 on its S102 site thereby allowing it to shuttle into the nucleus where it binds to the PIK3CA promoter to induce more p110a. This feedforward loop also causes an activation of signaling through RSK that enhances cellular invasion through phosphorylation of IkBa (Ghoda et al., 1997) , allowing NFkB to enter into the nucleus where it can induce uPA production (Sliva et al., 2002) . In closing, we determined for the first time that YB-1, which is a well-established oncogene for the development of mammary tumors, uses the induction of PIK3CA to bestow cellular invasion.
Materials and methods
Cell culture SUM149, HCC1937, MDA-MB-231 and SUM102 cells all express BLBC markers (Neve et al., 2006) . SUM149 and SUM102 cells (Asterand, Ann Arbor, MI, USA) were cultured according to the manufacturer's recommendations. MDA-MB-231 and HCC1937 cells (ATCC, Manassas, VA, USA) were grown as previously described .
siRNA and plasmid transfections Cells were transfected with 20 nM of siRNA to YB-1, PIK3CA, uPA and scrambled control using Lipofectamine RNAiMAX (Invitrogen, Burlington, Ontario, Canada) for 96 h. siRNA sequences are listed in Supplementary Table S1 . The empty vector, wt-YB-1, YB-1 S102A and YB-1 S102D have previously been described (Sutherland et The urokinase plasminogen activator (uPA) transcript levels determined by quantitative real-time PCR decreased after siYB-1 or siPIK3CA treatment in both SUM149 and HCC1937 cells. Furthermore, expression of p110a-CAAX in siYB-1-treated cells rescued the uPA levels. (c) The uPA transcript levels increased after expression of wt-YB-1 and even further after expression of YB-1 S102D. An increase in uPA levels was not detected after expression of YB-1 S102A. (d) Immunoblot of HCC1937 lysates indicates that the levels of P-RSK (S380) and its downstream target P-IkBa (S32/36) decreased with siYB-1 or siPIK3CA treatment. Furthermore, the expression of p110a-CAAX construct in siYB-1-treated cells rescued both the P-RSK (S380) and P-IkBa (S32/36) levels. Asterisk (*) represents P-value o0.05 comparing the labeled group to the scrambled control. Symbol c represents P-value o0.05 comparing the two indicated groups.
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Chromatin immunoprecipitation
YB-1 promoter complexes were isolated by ChIP as previously described (Wu et al., 2006) . The oligonucleotide sequences are provided in Supplementary Table S2 .
Electrophoretic mobility shift assay Nuclear and cytoplasmic proteins were fractionated using NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnology, Rockford, IL, USA). EMSAs were carried out using the Lightshift Chemiluminescent EMSA kit (Pierce Biotechnology) as previously described . Oligonucleotides used are listed in Supplementary Table S3. PIK3CA luciferase assay PIK3CA promoter 1a subcloned into a pGL3-basic vector (Promega, Madison, WI, USA) was previously described by us (Astanehe et al., 2008) . For the overexpression studies, cells were co-transfected with the YB-1 expression vector and both of PIK3CA 1a-pGL3 and pRL-TK. For knockdown studies, cells were transfected with DNA 48 h after siRNA treatment. Cells were harvested 24 h after transfection in 1 Â PLB buffer (Promega) and luciferase activity was measured using Dual Luciferase Reporter System (Promega) internally controlled with pRL-TK activity. Successful expression or silencing of YB-1 was confirmed by immunoblotting (data not shown).
Quantitative PCR RNA was isolated using the Qiagen RNeasy Mini kit (Qiagen, Mississauga, Ontario, Canada) and reverse-transcribed with random hexamers and SuperScript III (Invitrogen). TaqMan Universal Master Mix was used with the TaqMan Gene Expression Assay for PIK3CA, uPA and 18S (Applied Biosystems, Streetsville, Ontario, Canada), as well as primers and probes for YB-1 to detect transcript levels on an ABI Prism 7000 Sequence Detector. For PIK3CA copy number analysis, genomic DNA was extracted using Qiagen DNeasy blood and tissue kit (Qiagen). A panel of breast cancer cell lines was screened by amplifying 10 ng of DNA using TaqMan Gene Expression Assays for PIK3CA and 18S (Applied Biosystems).
Immunoblots
Proteins were harvested in ELB buffer (Wu et al., 2006) . The primary antibodies used were anti-total YB-1 (generous gift from Dr Colleen Nelson, University of British Columbia), anti-Flag M2 (Sigma, Oakville, Ontario, Canada), anti-p110a, anti-P-YB-1 (S102)
, anti-P-AKT (S473) , anti-P-S6RP
(S235/236)
, anti-P-RSK (S380) , anti-P-p70S6K
, anti-P-IkBa (S32/S36) and anti-actin (Cell Signaling Technology, Danvers, MA, USA).
Array comparative genomic hybridization HCC1937 and SUM149 were assayed for genetic alterations using the 26 819 duplicate spotted BAC clones (53 638 elements) selected from the previously described submegabase resolution tiling (SMRT) set to give optimal genome coverage (available at: http://www.bccrc.ca/arraycgh/; Deleeuw et al., 2007) . The BLBC specimens and MDA-MB-231 were assayed using an SMRT aCGH platform as previously described (Shadeo and Lam, 2006; Stratford et al., 2007) . To be classified as gain, there has to be a probability >80% (determined by Hidden Markov Model algorithm) and >0.15 log 2 ratio (determined by aCGH-Smooth software). NCBI Build 36.1 was used to identify gene locus and BAC position.
Immunofluorescence of xenograft sections and cells SUM149 xenograft frozen sections were fixed in 2% paraformaldehyde (PFA) and incubated with rabbit anti-p110a or rabbit-anti-P-YB-1 (S102) (Cell Signaling Technology) antibodies diluted in buffer containing 10% bovine serum albumin and 2% goat serum for 1 h at 21 1C in a humidified container. For PDK-1 membrane localization, cells were grown in chamber slides (Nalge Nunc International, Naperville, IL, USA), fixed in 2% PFA 96 h after siRNA transfection, permeabilized in 0.1% Triton X-100, blocked with protein block (Dako, Mississauga, Ontario, Canada) and incubated overnight at 4 1C with rabbit anti-P-PDK1 (S241) (Cell Signaling Technology). Alexa-488-labeled goat anti-rabbit secondary antibody was used for 1 h at 21 1C, and slides were mounted using Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). DAPI (46-diamidino-2-phenyl indole) or Hoechst dye was used for nuclear staining.
in vitro PI3K activity assay PI3K activity was assayed as previously reported (Gold et al., 1994) , with some modifications (see Supplementary materials and methods for details).
Invasion assay
At 96 h after siRNA transfection, cells were used in a Matrigel invasion assay following a protocol previously described (Woo et al., 2007) . Invaded cells were stained with 0.5 mg/ml of Hoechst 33258 (Sigma), mounted on glass slides and counted at Â 5 magnification using a Zeiss Axiophot microscope with a digital camera and Northern Eclipse 6.0 image analyzer (Empix Imaging) (Mississauga, Ontario, Canada). Figure 7 Proposed pathway of invasiveness in basal-like breast carcinoma (BLBC). Y-box binding protein-1 (YB-1) is phosphorylated on its S102 site by AKT and the p90 ribosomal S6 kinase (RSK). This phosphorylation allows YB-1 to shuttle into the nucleus where it binds to the PIK3CA promoter inducing transcription. The elevated p110a levels further lead to increased phosphatidylinositol-3-kinase (PI3K) activity and the eventual phosphorylation of RSK (S380) , a mechanism that is not well understood. Activated RSK then phosphorylates S6RP (S235/236) as well as IkBa (S32/36) . Once IkBa is phosphorylated it dissociates from nuclear factor-kB (NFkB) and is degraded. NFkB can then enter the nucleus and bind to the uPA promoter thereby inducing its transcription. Finally the elevated uPA levels increase invasion.
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